NICE rejects Erbitux in head and neck cancer
pharmafile | June 24, 2009 | News story | Research and Development, Sales and Marketing |Â Â Erbitux, Merck Serono, NICEÂ
Related Content
East London pharmacies pilot cholesterol-lowering injections to cut waiting times
A pilot scheme in east London is offering cholesterol-lowering injections at community pharmacies to help …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for …
NICE recommends allergy immunotherapy tablets for younger children
NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …
